
The Latest Breakthroughs in mHSPC (2025) Webcast/Podcast

In response to critical insights from the American Urological Association's (AUA) Advanced Prostate Cancer Global Needs Assessment, the AUA proud to present The Latest Breakthroughs in Metastatic Hormone Sensitive Prostate Cancer (mHSPC).
This dynamic program will feature a virtual panel discussion with leading experts, exploring cutting-edge developments in mHSPC treatment and offering practical insights for clinical application. Whether you’re a urologist, resident, or advanced practice provider, this course will equip you with the knowledge needed to deliver optimal, evidence-based care in a rapidly evolving landscape.
ACKNOWLEDGEMENTS
Support provided by an independent educational grant from:
- AstraZeneca
- Bayer HealthCare Pharmaceuticals Inc.
Target Audience
- Urologists
- APPs
- Residents/Fellows
Learning Objectives
After participating in this CME activity, participants will be able to:
- Evaluate the concept of personalized therapy and its importance in the treatment of de novo mHSPC.
- Implement current clinical guidelines for biomarker testing in mHSPC.
- Explain the role of the PI3K/AKT pathway in prostate cancer biology.
- Explore collaborations between urologists, oncologists, radiologists, and other healthcare professionals in managing de novo mHSPC.
- Employ strategies to manage and mitigate common adverse events associated with AKT inhibitors and other therapies used in mHSPC.
Welcome and Introductions
Segment 1: Personalized Therapy and its Importance
Segment 2: Current clinical guidelines for biomarker testing in mHSPC
Segment 3: Role of the PI3K/AKT pathway in prostate cancer biology
Segment 4: Collabs between healthcare professionals in managing mHSPC
Segment 5: Strategies to manage and mitigate common adverse events
Wrap-up
| Name | Company Name | Relationship Type | End Date |
| Barata, Pedro | Exelixis | Consultant or Advisor | Current |
| Caris Life Sciences | Consultant or Advisor | Current | |
| Pfizer | Consultant or Advisor | Current | |
| Astellas | Consultant or Advisor | Current | |
| Seattle Genetics | Scientific Study or Trial | Current | |
| Bayer | Consultant or Advisor | Current | |
| Novartis | Consultant or Advisor | Current | |
| AstraZeneca | Consultant or Advisor | Current | |
| Ipsen | Consultant or Advisor | Current | |
| Eisai | Meeting Participant or Lecturer | Current | |
| Hastings, Rachel | No relevant financial relationships to disclose | ||
| Nguyen, Paul L | Novartis | Consultant or Advisor | Current |
| Janssen Oncology | Consultant or Advisor | Current | |
| MDx Health | Consultant or Advisor | Current | |
| Blue Earth | Consultant or Advisor | Current | |
| Punnen, Sanoj | Decipher Biosciences | Meeting Participant or Lecturer | Current |
| ExosomeDx | Meeting Participant or Lecturer | Current | |
| telix | Consultant or Advisor | Current | |
| Williams, Michael B. | Astellas | Scientific Study or Trial | Current |
| Pacific Edge Diagnostics | Consultant or Advisor | Current | |
| Ferring | Consultant or Advisor | Current | |
| Olympus | Consultant or Advisor | Current | |
| Pfizer | Consultant or Advisor | Current | |
| UroGPO | Meeting Participant or Lecturer | Current | |
| Janssen Oncology | Consultant or Advisor | Current | |
EDUCATION COUNCIL DISCLOSURE
Education Council DTL 2025_1.pdf
COI REVIEW WORK GROUP DISCLOSURES
COI Review Workgroup DTL 2025_1.pdf
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
AUA ACCREDITATION INFORMATION
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 1.50 hours
Release Date: September, 2025
Expiration Date: September, 2026
ACCREDITATION:
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The American Urological Association designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS:
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
DISCLAIMER:
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
REPRODUCTION PERMISSION:
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Non-Physician Participation

Facebook
X
LinkedIn
Forward